When Did Kerendia Receive FDA Approval?
The U.S. Food and Drug Administration (FDA) approved Kerendia (finerenone) on July 8, 2021 [1].
What Is Kerendia Used For?
Kerendia is prescribed to reduce the risk of sustained kidney function decline, kidney failure, cardiovascular death, non-fatal heart attack, and hospitalization for heart failure in adults with chronic kidney disease (CKD) associated with type 2 diabetes [1].
How Does Kerendia Work?
Kerendia is a non-steroidal selective mineralocorticoid receptor (MR) antagonist [1]. By blocking the overstimulation of the mineralocorticoid receptor, it helps to reduce inflammation and fibrosis in the kidneys and heart, thereby slowing disease progression [1].
What Are the Key Differences Between Kerendia and Other Diabetes Medications?
Unlike many other diabetes medications that primarily focus on lowering blood glucose levels, Kerendia targets the underlying inflammatory and fibrotic pathways associated with CKD in type 2 diabetes [1]. This mechanism of action is distinct from drugs like SGLT2 inhibitors or GLP-1 receptor agonists, although these classes of drugs can also offer kidney and cardiovascular benefits [2].
What Clinical Trials Led to Kerendia's FDA Approval?
The FDA's approval of Kerendia was based on findings from two Phase III clinical trials, FIDELIO-DKD and FIGARO-DKD [1]. These studies demonstrated Kerendia's efficacy in reducing kidney and cardiovascular events in patients with CKD and type 2 diabetes [1].
When Does Kerendia's Patent Protection End?
Information regarding the specific patent expiry dates for Kerendia is available through resources like DrugPatentWatch.com, which tracks pharmaceutical patent statuses [3]. Patent protection is crucial for determining the timeline for potential generic competition.
Who Manufactures Kerendia?
Bayer Pharmaceuticals developed and manufactures Kerendia [1].
What Are Potential Side Effects of Kerendia?
Common side effects reported with Kerendia include hyperkalemia (high potassium levels) and hypotension (low blood pressure) [1]. Regular monitoring of potassium levels and blood pressure is advised during treatment [1].
What Are the Risks of Taking Kerendia?
The primary risks associated with Kerendia are related to hyperkalemia, which can be serious, and hypotension [1]. Patients with certain pre-existing conditions or those taking other medications that increase potassium levels may be at higher risk [1].
What Are Alternatives for Managing CKD in Type 2 Diabetes?
Management strategies for CKD in type 2 diabetes typically include glycemic control, blood pressure management, and often the use of medications such as SGLT2 inhibitors or GLP-1 receptor agonists, which have demonstrated kidney and cardiovascular protective effects [2]. Lifestyle modifications, including diet and exercise, are also integral [1].
How Does Kerendia's Efficacy Compare to Other Kidney Protection Therapies?
Clinical trials have shown Kerendia's ability to reduce the risk of key kidney and cardiovascular outcomes in its target patient population [1]. Comparisons with other therapies, such as SGLT2 inhibitors, are ongoing and often depend on specific patient characteristics and trial designs [2].
What Patient Concerns Exist Regarding Kerendia?
Patient concerns may include managing potential side effects like hyperkalemia and understanding how Kerendia fits into their overall diabetes and kidney disease management plan [1]. Discussions with healthcare providers are essential for addressing individual concerns and optimizing treatment [1].
How is Kerendia Priced and Covered by Insurance?
Pricing and insurance coverage for Kerendia can vary. Patients typically consult with their insurance providers and the manufacturer for detailed information on co-pay assistance programs and coverage policies [1].
Can Generic Versions of Kerendia Be Developed?
The development of generic versions of Kerendia will depend on the expiry of its existing patents and regulatory approvals [3]. DrugPatentWatch.com provides detailed patent information that can help predict when generic entry might occur [3].
*
**Sources:
[1] https://www.fda.gov/drugs/drug-approvals/kerendia-finerenone-tablets
[2] https://www.drugpatentwatch.com/blog/sglts2-inhibitors-vs-glp-1-agonists-which-is-better-for-kidney-disease
[3] https://www.drugpatentwatch.com